Cover Image

Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was considered a promising treatment for patients with peritoneal metastasis from colorectal cancer. However, the recently published randomized controlled PRODIGE 7 trial failed to demonstrate survival benefits thr...

Full description

Saved in:
Bibliographic Details
Main Authors: Seyfried, Nick (Author) , Burkard, Markus (Author) , Yurttas, Can (Author) , Oswald, Benedikt (Author) , Tolios, Alexander (Author) , Herster, Franziska (Author) , Kauer, Joseph (Author) , Jäger, Tarkan (Author) , Königsrainer, Ingmar (Author) , Thiel, Karolin (Author) , Quante, Markus (Author) , Rammensee, Hans-Georg (Author) , Venturelli, Sascha (Author) , Schwab, Matthias (Author) , Königsrainer, Alfred (Author) , Beckert, Stefan (Author) , Löffler, Markus W. (Author)
Format: Article (Journal)
Language:English
Published: 2022
In: Cancers
Year: 2022, Volume: 14, Issue: 5, Pages: 1-19
ISSN:2072-6694
DOI:10.3390/cancers14051158
Online Access:Resolving-System, kostenfrei: https://doi.org/10.3390/cancers14051158
Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers14051158
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/14/5/1158
Get full text
Author Notes:Nick Seyfried, Can Yurttas, Markus Burkard, Benedikt Oswald, Alexander Tolios, Franziska Herster, Joseph Kauer, Tarkan Jäger, Ingmar Königsrainer, Karolin Thiel, Markus Quante, Hans-Georg Rammensee, Sascha Venturelli, Matthias Schwab, Alfred Königsrainer, Stefan Beckert and Markus W. Löffler

MARC

LEADER 00000caa a2200000 c 4500
001 1794855939
003 DE-627
005 20251101215949.0
007 cr uuu---uuuuu
008 220307s2022 xx |||||o 00| ||eng c
024 7 |a 10.3390/cancers14051158  |2 doi 
035 |a (DE-627)1794855939 
035 |a (DE-599)KXP1794855939 
035 |a (OCoLC)1341445726 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Seyfried, Nick  |e VerfasserIn  |0 (DE-588)1256294691  |0 (DE-627)1800368461  |4 aut 
245 1 0 |a Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model  |c Nick Seyfried, Can Yurttas, Markus Burkard, Benedikt Oswald, Alexander Tolios, Franziska Herster, Joseph Kauer, Tarkan Jäger, Ingmar Königsrainer, Karolin Thiel, Markus Quante, Hans-Georg Rammensee, Sascha Venturelli, Matthias Schwab, Alfred Königsrainer, Stefan Beckert and Markus W. Löffler 
264 1 |c 2022 
300 |a 1 Online-Ressource  |b Diagramme 
300 |a 19 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a This article belongs to the special issue "Preclinical models of solid malignancies" 
500 |a Gesehen am 02.07.2022 
520 |a Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was considered a promising treatment for patients with peritoneal metastasis from colorectal cancer. However, the recently published randomized controlled PRODIGE 7 trial failed to demonstrate survival benefits through the addition of short-term oxaliplatin-based HIPEC. Constituting a complex multifactorial treatment, we investigated HIPEC in a preclinical model concerning the elimination of minimal tumor residues, thereby aiming to better understand the size of effects and respective clinical trial results. Patient samples of peritoneal perfusates obtained during HIPEC treatments and oxaliplatin-containing solutions at clinically relevant dosages, conforming with established HIPEC protocols, were assessed regarding their ability to eliminate modelled ~100 µm thickness cancer cell layers. Impedance-based real-time cell analysis and classical end-point assays were used. Flow cytometry was employed to determine the effect of different HIPEC drug solvents on tumor cell properties. Effectiveness of peritoneal perfusate patient samples and defined oxaliplatin-containing solutions proved limited but reproducible. HIPEC simulations for 30 min reduced the normalized cell index below 50% with peritoneal perfusates from merely 3 out of 9 patients within 72 h, indicating full-thickness cytotoxic effects. Instead, prolonging HIPEC to 1 h enhanced these effects and comprised 7 patients’ samples, while continuous drug exposure invariably resulted in complete cell death. Further, frequently used drug diluents caused approximately 25% cell size reduction within 30 min. Prolonging oxaliplatin exposure improved effectiveness of HIPEC to eliminate micrometastases in our preclinical model. Accordingly, insufficient penetration depth, short exposure time, and the physicochemical impact of drug solvents may constitute critical factors. 
650 4 |a colorectal cancer 
650 4 |a micrometastasis model 
650 4 |a peritoneal carcinomatosis 
650 4 |a peritoneal metastasis 
650 4 |a PRODIGE 7 trial 
700 1 |a Burkard, Markus  |e VerfasserIn  |0 (DE-588)1207509337  |0 (DE-627)169385807X  |4 aut 
700 1 |a Yurttas, Can  |e VerfasserIn  |4 aut 
700 1 |a Oswald, Benedikt  |e VerfasserIn  |4 aut 
700 1 |a Tolios, Alexander  |e VerfasserIn  |4 aut 
700 1 |a Herster, Franziska  |e VerfasserIn  |4 aut 
700 1 |a Kauer, Joseph  |d 1992-  |e VerfasserIn  |0 (DE-588)1161466134  |0 (DE-627)102475524X  |0 (DE-576)50654382X  |4 aut 
700 1 |a Jäger, Tarkan  |e VerfasserIn  |4 aut 
700 1 |a Königsrainer, Ingmar  |e VerfasserIn  |4 aut 
700 1 |a Thiel, Karolin  |e VerfasserIn  |4 aut 
700 1 |a Quante, Markus  |e VerfasserIn  |4 aut 
700 1 |a Rammensee, Hans-Georg  |e VerfasserIn  |4 aut 
700 1 |a Venturelli, Sascha  |e VerfasserIn  |0 (DE-588)138098387  |0 (DE-627)696337770  |0 (DE-576)306563460  |4 aut 
700 1 |a Schwab, Matthias  |e VerfasserIn  |4 aut 
700 1 |a Königsrainer, Alfred  |e VerfasserIn  |4 aut 
700 1 |a Beckert, Stefan  |e VerfasserIn  |4 aut 
700 1 |a Löffler, Markus W.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Cancers  |d Basel : MDPI, 2009  |g 14(2022), 5, Artikel-ID 1158, Seite 1-19  |h Online-Ressource  |w (DE-627)614095670  |w (DE-600)2527080-1  |w (DE-576)313958548  |x 2072-6694  |7 nnas  |a Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model 
773 1 8 |g volume:14  |g year:2022  |g number:5  |g elocationid:1158  |g pages:1-19  |g extent:19  |a Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model 
856 4 0 |u https://doi.org/10.3390/cancers14051158  |x Resolving-System  |z kostenfrei 
856 4 0 |u https://doi.org/10.3390/cancers14051158  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2072-6694/14/5/1158  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220702 
993 |a Article 
994 |a 2022 
998 |g 1161466134  |a Kauer, Joseph  |m 1161466134:Kauer, Joseph  |d 910000  |d 910100  |e 910000PK1161466134  |e 910100PK1161466134  |k 0/910000/  |k 1/910000/910100/  |p 7 
999 |a KXP-PPN1794855939  |e 4160257720 
BIB |a Y 
SER |a journal 
JSO |a {"note":["This article belongs to the special issue \"Preclinical models of solid malignancies\"","Gesehen am 02.07.2022"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1794855939","language":["eng"],"title":[{"title":"Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model","title_sort":"Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model"}],"person":[{"family":"Seyfried","given":"Nick","display":"Seyfried, Nick","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Burkard, Markus","roleDisplay":"VerfasserIn","role":"aut","family":"Burkard","given":"Markus"},{"family":"Yurttas","given":"Can","display":"Yurttas, Can","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Oswald, Benedikt","given":"Benedikt","family":"Oswald"},{"roleDisplay":"VerfasserIn","display":"Tolios, Alexander","role":"aut","family":"Tolios","given":"Alexander"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Herster, Franziska","given":"Franziska","family":"Herster"},{"given":"Joseph","family":"Kauer","role":"aut","display":"Kauer, Joseph","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Jäger, Tarkan","role":"aut","family":"Jäger","given":"Tarkan"},{"given":"Ingmar","family":"Königsrainer","role":"aut","roleDisplay":"VerfasserIn","display":"Königsrainer, Ingmar"},{"given":"Karolin","family":"Thiel","role":"aut","roleDisplay":"VerfasserIn","display":"Thiel, Karolin"},{"family":"Quante","given":"Markus","display":"Quante, Markus","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Rammensee","given":"Hans-Georg","display":"Rammensee, Hans-Georg","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Venturelli, Sascha","given":"Sascha","family":"Venturelli"},{"given":"Matthias","family":"Schwab","role":"aut","roleDisplay":"VerfasserIn","display":"Schwab, Matthias"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Königsrainer, Alfred","given":"Alfred","family":"Königsrainer"},{"roleDisplay":"VerfasserIn","display":"Beckert, Stefan","role":"aut","family":"Beckert","given":"Stefan"},{"family":"Löffler","given":"Markus W.","roleDisplay":"VerfasserIn","display":"Löffler, Markus W.","role":"aut"}],"physDesc":[{"noteIll":"Diagramme","extent":"19 S."}],"relHost":[{"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"id":{"eki":["614095670"],"zdb":["2527080-1"],"issn":["2072-6694"]},"origin":[{"publisherPlace":"Basel","publisher":"MDPI","dateIssuedKey":"2009","dateIssuedDisp":"2009-"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Cancers","title":"Cancers"}],"recId":"614095670","language":["eng"],"note":["Gesehen am 27.05.2020"],"disp":"Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis ModelCancers","type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"volume":"14","text":"14(2022), 5, Artikel-ID 1158, Seite 1-19","extent":"19","year":"2022","pages":"1-19","issue":"5"},"pubHistory":["1.2009 -"]}],"origin":[{"dateIssuedDisp":"2022","dateIssuedKey":"2022"}],"id":{"eki":["1794855939"],"doi":["10.3390/cancers14051158"]},"name":{"displayForm":["Nick Seyfried, Can Yurttas, Markus Burkard, Benedikt Oswald, Alexander Tolios, Franziska Herster, Joseph Kauer, Tarkan Jäger, Ingmar Königsrainer, Karolin Thiel, Markus Quante, Hans-Georg Rammensee, Sascha Venturelli, Matthias Schwab, Alfred Königsrainer, Stefan Beckert and Markus W. Löffler"]}} 
SRT |a SEYFRIEDNIPROLONGEDE2022 

Similar Items